OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
US-2016347837-A1 · Dec 1, 2016 · US
OPTIMIZED Fc VARIANTS
US2016304589A9 · US · A9
| Field | Value |
|---|---|
| Publication number | US-2016304589-A9 |
| Application number | US-201414507783-A |
| Country | US |
| Kind code | A9 |
| Filing date | Oct 6, 2014 |
| Priority date | Mar 3, 2003 |
| Publication date | Oct 20, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
First claim
Opening claim text (preview).
We claim: 1 . A protein comprising an Fc variant of a parent human IgG Fc polypeptide, said Fc variant comprising an amino acid substitution S267E in the Fc region, wherein said Fc variant exhibits increased binding to FcγRIIb as compared to the parent Fc polypeptide and wherein numbering is according to the EU index. 2 . The protein according to claim 1 , where said protein is an antibody or immunoadhesion. 3 . The protein according to claim 2 , where said protein is an antibody. 4 . The protein according to claim 2 , wherein said protein is an antibody and wherein said antibody is selected from the group consisting of a humanized antibody and a monoclonal antibody. 5 . The protein according to claim 4 , wherein said antibody is a monoclonal antibody. 6 . The protein according to claim 4 , wherein said antibody is a humanized antibody. 7 . The protein according to claim 1 , wherein said parent Fc polypeptide is a human IgG1. 8 . The protein according to claim 2 , wherein said protein is an immunoadhesin. 9 . A protein comprising an Fc variant of a parent human IgG Fc polypeptide, said Fc variant comprising an amino acid substitution S267D in the Fc region, wherein said Fc variant exhibits increased binding to FcγRIIb as compared to the parent Fc polypeptide and wherein numbering is according to the EU index. 10 . The protein according to claim 9 , wherein said protein is an antibody or immunoadhesion. 11 . The protein according to claim 10 , where said protein is an antibody. 12 . The protein according to claim 10 , wherein said protein is an antibody, and wherein said antibody is selected from the group consisting of a humanized antibody and a monoclonal antibody. 13 . The protein according to claim 12 , wherein said antibody is a monoclonal antibody. 14 . The protein according to claim 12 , wherein said antibody is a humanized antibody. 15 . The protein according to claim 9 , wherein said parent Fc polypeptide is a human IgG1. 16 . The protein according to claim 10 , wherein said protein is an immunoadhesin.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- C07K16/2893Primary
against CD52 · CPC title
against CD20 · CPC title
Antibody-dependent cellular cytotoxicity [ADCC] · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016304589A9 cover?
- The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2893. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A9). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).